Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 26Lymphoma 22Leukemia, Myeloid, Acute 21Leukemia 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Non-Hodgkin 17Myelodysplastic Syndromes 16Hodgkin Disease 15Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 6Primary Myelofibrosis 5Neoplasms, Plasma Cell 5Myeloproliferative Disorders 5Recurrence 4Neuroblastoma 4Graft vs Host Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Polycythemia Vera 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Juvenile 3Ganglioneuroblastoma 3Thrombocythemia, Essential 2Testicular Neoplasms 2Rhabdomyosarcoma 2

Interventions

Lenalidomide 8Dexamethasone 6Calcium Dobesilate 6Melphalan 3elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Peripheral Blood Stem Cell Transplantation 2Bortezomib 2pomalidomide 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1Watchful Waiting 1Urination 1Transplantation, Autologous 1Stem Cell Transplantation 1Receptors, Interleukin-6 1Observation 1Nivolumab 1Metformin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1IPH-2101 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Smoldering Multiple Myeloma × Stem Cell Transplantation × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡